HLS Therapeutics Inc.
HLTRF
$3.36
-$0.07-1.98%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.23% | -4.08% | -2.40% | 1.20% | -2.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.23% | -4.08% | -2.40% | 1.20% | -2.02% |
| Cost of Revenue | 1.25% | 3.67% | 3.98% | 26.16% | 7.78% |
| Gross Profit | -3.53% | -6.81% | -4.59% | -6.84% | -5.24% |
| SG&A Expenses | -15.62% | -18.11% | -19.67% | -19.52% | 3.02% |
| Depreciation & Amortization | 0.53% | 0.05% | -6.37% | -9.44% | -22.89% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.58% | -6.84% | -9.64% | -7.07% | -6.64% |
| Operating Income | 179.00% | 27.42% | 61.58% | 36.82% | 72.88% |
| Income Before Tax | 32.54% | 19.74% | -55.60% | 27.32% | 44.84% |
| Income Tax Expenses | -861.18% | 71.19% | -94.06% | 20.69% | 13.33% |
| Earnings from Continuing Operations | 55.84% | 19.12% | 51.76% | 27.35% | 44.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.84% | 19.12% | 51.76% | 27.35% | 44.03% |
| EBIT | 179.00% | 27.42% | 61.58% | 36.82% | 72.88% |
| EBITDA | 11.25% | 14.44% | 22.81% | 29.29% | -20.71% |
| EPS Basic | 60.00% | 18.11% | 51.65% | 27.04% | 41.18% |
| Normalized Basic EPS | 38.88% | 18.44% | 49.75% | 24.66% | 37.29% |
| EPS Diluted | 61.94% | 18.11% | 50.00% | 26.78% | 38.68% |
| Normalized Diluted EPS | 38.88% | 18.44% | 49.75% | 24.66% | 37.29% |
| Average Basic Shares Outstanding | 10.40% | -1.23% | -0.24% | -0.46% | -4.85% |
| Average Diluted Shares Outstanding | 10.40% | -1.23% | -0.24% | -0.46% | -4.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |